2002 News Archive
Holding in Company
11 December 2002
The Company has received a notification from AVIVA plc on behalf of Morley Fund Management Limited and AVIVA plc
Protherics PLC Interim results
03 December 2002
Protherics plc, the UK biopharmaceutical company, today announces interim results for the six months to 30 September 2002.
Protherics Redeems Convertible Debentures Option
25 November 2002
Protherics PLC (Protherics or the Company), announces today that it has reached an agreement that no further Convertible Debentures will be issued by the Company pursuant to the Subscription Agreement dated 20 April 2000 between the Company, Fisher Capital Ltd, Wingate Capital Ltd and Leonardo LP.
Arthur Rushton resignation
25 October 2002
Protherics PLC, (Protherics or the Company) announces today that, due to ill health, Arthur Rushton has resigned as a Director of Protherics with immediate effect.
Chairman~s Trading Statement For AGM
23 July 2002
At the time we announced our results for the year ended 31 March 2002, I was pleased to look back on a year of excellent progress, with turnover up 89% to 7.9 million, the successful launch of a second product, DigiFab
Business Development Director Appointment
09 July 2002
Protherics PLC the UK biotechnology company with two FDA approvals, has appointed Dr Ian Scoular as Business Development Director, with immediate effect.
Protherics Files Patent
19 June 2002
Protherics PLC, the UK biotechnology company with two FDA approved products, has filed patents with the UK Patent Office for a series of immunogens used in a vaccine it is developing to help prevent the spread of cancer (metastases).
Holding in Company
07 June 2002
The Company received a notification today from Bradshaw Asset Management Limited on behalf of Victory Capital plc
Product Update
25 April 2002
CroFab - Resumption of filling and freeze-drying after short delay Angiotensin vaccine - Further trials planned following early phase II success.
Holding in Company
25 March 2002
The Company has received a notification from Citadel Limited Partnership that in their capacity as fund manager
Phase II success
25 March 2002
Protherics PLC announces that it has achieved successful results from early phase II trials indicating that its angiotensin vaccine is
CroFab update
25 March 2002
Protherics PLC ("Protherics") has been informed by the third party responsible for freeze-drying and filling of CroFab
Director Shareholding
16 January 2002
2) Name of Director
Dr Andrew Heath
Director Shareholding
16 January 2002
2) NAME OF DIRECTOR
JAMES CAMPBELL CHRISTIE
Director Shareholding
16 January 2002
2) NAME OF DIRECTOR
BARRINGTON MARSHALL RILEY
Director Shareholding
16 January 2002
2) NAME OF DIRECTOR
ANDREW JOHN HEATH
Additional Listing
10 January 2002
Protherics PLC ("Protherics") announces that Wingate Capital Ltd ("Wingate") and Fisher Capital Ltd ("Fisher") have, following conversion notices served
Additional Listing
04 January 2002
Protherics PLC ("Protherics") announces that Wingate Capital Ltd ("Wingate") and Fisher Capital Ltd ("Fisher") have, following conversion notices served
Holding in Company
03 January 2002
The Company received a notification yesterday from Bradshaw Asset Management Limited on behalf of Victory Capital plc that following a ...
2007 News
2006 News Archive
2005 News Archive
2004 News Archive
2003 News Archive
2002 News Archive
2001 News Archive
2000 News Archive